Patents Examined by Kathrien A Cruz
  • Cannabidiol for the prevention and treatment of graft-versus-host disease
    Patent number: 9956182
    Abstract: The invention provides methods for preventing, ameliorating and treating the acute and chronic forms of graft-versus-host disease (GVHD) by using Cannabidiol compositions.
    Type: Grant
    Filed: April 29, 2014
    Date of Patent: May 1, 2018
    Assignee: MOR RESEARCH APPLICATIONS LTD.
    Inventor: Moshe Yeshurun
  • Tricyclic indole Mcl-1 inhibitors and uses thereof
    Patent number: 9949965
    Abstract: The present invention provides for compounds that inhibit the activity of an anti-apoptotic Bcl-2 family member Myeloid cell leukemia-1 (Mcl-1) protein. The present invention also provides for pharmaceutical compositions as well as methods for using compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein.
    Type: Grant
    Filed: October 16, 2015
    Date of Patent: April 24, 2018
    Assignee: Vanderbilt University
    Inventors: Taekyu Lee, Jason P. Burke, Edward T. Olejniczak, Johannes Belmar, Zhiguo Bian, Stephen W. Fesik
  • Constrained tricyclic sulfonamides
    Patent number: 9937180
    Abstract: Tricyclic chemical modulators of protein phosphatase 2A are disclosed. The compounds are useful to treat cancer, age-onset proteotoxicity, stress-induced depression, inflammation, and acne.
    Type: Grant
    Filed: March 10, 2015
    Date of Patent: April 10, 2018
    Assignee: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
    Inventors: Michael Ohlmeyer, David Kastrinsky
  • Sulfonamides derived from tricyclyl-2-aminocycloalkanols as anticancer agents
    Patent number: 9937186
    Abstract: A genus of arylsulfonamide derivatives of aminocycloalkanols is disclosed. The compounds are of the following genus: The compounds induce FOXO1 transcription factor translocation to the nucleus by modulating PP2A and, as a consequence, exhibit anti-proliferative effects. They are useful in the treatment of a variety of disorders, including as a monotherapy in cancer treatment, or used in combination with other drugs to restore sensitivity to chemotherapy where resistance has developed.
    Type: Grant
    Filed: March 10, 2015
    Date of Patent: April 10, 2018
    Assignee: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
    Inventors: Michael Ohlmeyer, David Kastrinsky
  • Method for treating secondary hyperparathyroidism in CKD
    Patent number: 9925147
    Abstract: A stable, controlled release formulation for oral dosing of vitamin D compounds is disclosed. The formulation is prepared by incorporating one or more vitamin D compounds into a solid or semi-solid mixture of waxy materials. Oral dosage forms can be prepared by melt-blending the components described herein and filling gelatin capsules with the formulation.
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: March 27, 2018
    Assignees: OPKO RENAL, LLC, OPKO IRELAND GLOBAL HOLDINGS, LIMITED
    Inventors: Charles W. Bishop, Samir P. Tabash, Sammy A. Agudoawu, Jay A. White, Eric J. Messner, P. Martin Petkovich, Keith H. Crawford
  • Methods and compositions for inhibition of ATR and FANCD2 activation
    Patent number: 9918962
    Abstract: This invention is announcing a composition of flavonoid skeleton in the formula I or formula II compound, wherein each of the substituents is given the definition as set forth in the specification and claims. This composition have the capacity to treating or preventing a virus infection in a subject.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: March 20, 2018
    Assignee: KAOHSIUNG MEDICAL UNIVERSITY
    Inventors: Hui-Chun Wang, Yang-Chang Wu, Fang-Rong Chang, Chin-Chung Wu
  • Emesis treatment
    Patent number: 9918949
    Abstract: A method of treating or preventing emesis through the administration of an effective dosage of a 2-(amino)tetralin compound in which one of the S or R enantiomers of the 2-(amino) tetralin compound is present in the composition in excess of the other enantiomer, and compositions comprising such a 2-(amino)tetralin compound in which the ratio of the S and R enantiomers is at least 2:1.
    Type: Grant
    Filed: July 30, 2014
    Date of Patent: March 20, 2018
    Assignee: Repurposed Therapeutics, Inc.
    Inventors: David Helton, James Lucot
  • Methods for controlled release oral dosage of a vitamin D compound
    Patent number: 9918940
    Abstract: A stable, controlled release formulation for oral dosing of vitamin D compounds is disclosed. The formulation is prepared by incorporating one or more vitamin D compounds into a solid or semi-solid mixture of waxy materials. Oral dosage forms can be prepared by melt-blending the components described herein and filling gelatin capsules with the formulation.
    Type: Grant
    Filed: June 16, 2014
    Date of Patent: March 20, 2018
    Assignees: OPKO IRELAND GLOBAL HOLDINGS, LTD.
    Inventors: Charles W. Bishop, Samir P. Tabash, Sammy A. Agudoawu, Jay A. White, Keith H. Crawford, Eric J. Messner, P. Martin Petkovich
  • Pyridic ketone derivatives, method of preparing same, and pharmaceutical application thereof
    Patent number: 9914703
    Abstract: Pyridone derivatives, methods of preparing the pyridone derivatives, and methods of using the pyridone derivatives are provided. In particular, pyridone derivatives of formula (I), and pharmaceutical salts thereof are provided. The pyridone derivatives are useful as mitogen-activated protein kinase kinase (MEK) inhibitors, and can be used as therapeutic agents for treating cancer.
    Type: Grant
    Filed: September 5, 2014
    Date of Patent: March 13, 2018
    Assignees: Shanghai Hengrui Pharmaceutical Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Wangyang Tu, Haitang Zhang, Guoji Xu, Jiangtao Chi
  • Sweetness receptor antagonist
    Patent number: 9907766
    Abstract: Sweetness receptor antagonists represented by formula (I): wherein each symbol is described herein, are useful for the prophylaxis or treatment of metabolic syndrome, diabetes, obesity and the like.
    Type: Grant
    Filed: December 23, 2016
    Date of Patent: March 6, 2018
    Assignee: AJINOMOTO CO., INC.
    Inventors: Yoshiro Kitahara, Koji Ohsumi, Seiji Kitajima, Shimpei Ogawa
  • Cobalt-polypyridyl complex for treatment of cancer, a pharmaceutical composition and a kit comprising it
    Patent number: 9895338
    Abstract: A method for treating a subject suffering from a cancer, in particular a multidrug-resistant cancer includes administrating a cobalt-polypyridyl complex to the subject. A method for suppressing the growth of cancer cells, in particular inducing autophagy of the cancer cells, inducing cell cycle arrest of the cancer cells and/or inhibiting cell invasion of the cancer cells and for specifically targeting cancer cells with multidrug-resistance includes contacting said cancer cells with the cobalt-polypyridyl complex. A pharmaceutical composition and a kit are provided and include the cobalt-polypyridyl complex. Unexpectedly, the cobalt-polypyridyl complex is especially suitable to treat cancer, in particular multidrug-resistant cancer with an exceptionally increased cytotoxic activity towards multidrug-resistant cancer cells.
    Type: Grant
    Filed: August 22, 2016
    Date of Patent: February 20, 2018
    Assignee: Macau University of Science and Technology
    Inventors: Kam Wai Wong, Man Chung Wong
  • Method for treating tumors with cannabinoids
    Patent number: 9895343
    Abstract: A method for treating radiotherapy- or chemotherapy-induced cognitive or emotional impairment by topically administering a cannabinoid. Also provided is a method for treating a tumor by topically administering a cannabinoid together with radiotherapy and/or chemotherapy.
    Type: Grant
    Filed: June 1, 2016
    Date of Patent: February 20, 2018
    Assignee: GLIA, LLC
    Inventors: Kenneth I. Sawyer, Wei-wei Chang
  • Anti-cancer lead molecule
    Patent number: 9890106
    Abstract: Derivatives of plumbagin can be selectively cytotoxic to breast cancer cells. Derivative ‘A’ (Acetyl Plumbagin) has emerged as a lead molecule for testing against estrogen positive breast cancer and has shown low hepatotoxicity as well as overall lower toxicity in nude mice model. The toxicity of derivative ‘A’ was determined to be even lower than vehicle control (ALT and AST markers). The possible mechanism of action identified based on the microarray experiments and pathway mapping shows that derivative ‘A’ could be acting by altering the cholesterol-related mechanisms. The low toxicity profile of derivative ‘A’ highlights its possible role'as future anti-cancer drug and/or as an adjuvant drug to reduce the toxicity of highly toxic chemotherapeutic'drugs.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: February 13, 2018
    Assignee: KING ABDULLAH UNIVERSITY OF SCIENCE & TECHNOLOGY
    Inventors: Sunil Sagar, Mandeep Kaur, Luke E. Esau
  • Cannabidiol for treatment of severe and refractory graft-versus-host disease
    Patent number: 9889100
    Abstract: The invention provides methods for preventing, ameliorating and treating the acute and chronic forms of graft-versus-host disease (GVHD) by using Cannabidiol compositions.
    Type: Grant
    Filed: May 2, 2016
    Date of Patent: February 13, 2018
    Assignee: MOR RESEARCH APPLICATIONS LTD.
    Inventor: Moshe Yeshurun
  • Piperazinyl derivatives for the treatment of cancer
    Patent number: 9877962
    Abstract: Piperazinyl derivatives of formula (I) and their use as a drug, particularly for the treatment of cancer, are disclosed. Also disclosed are pharmaceutical compositions comprising the piperazinyl derivatives, and methods for synthesizing the piperazinyl derivatives.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: January 30, 2018
    Inventor: Marc-Henry Pitty
  • Compounds useful as immunomodulators
    Patent number: 9872852
    Abstract: Disclosed are compounds of Formula (I): (I). Also disclosed are methods of using such compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of virological diseases or disorders and cancer.
    Type: Grant
    Filed: September 2, 2014
    Date of Patent: January 23, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Louis S. Chupak, Xiaofan Zheng
  • Method for treating pancreatic cancer
    Patent number: 9872912
    Abstract: A method for treating pancreatic cancer is provided. The method comprises administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical formulation, wherein the pharmaceutical formulation comprises (Z)-butylidenephthalide and is substantially free of (E)-butylidenephthalide.
    Type: Grant
    Filed: October 21, 2014
    Date of Patent: January 23, 2018
    Assignee: CHINA MEDICAL UNIVERSITY
    Inventors: Tzyy-Wen Chiou, Horng-Jyh Harn, Shinn-Zong Lin, Yi-Wen Chou, Mao-Hsuan Huang
  • Waxes derived from metathesized natural oils and amines and methods of making
    Patent number: 9867771
    Abstract: Wax compositions derived from metathesized natural oils and amines and methods of making wax compositions from metathesized natural oils and amines are provided. The wax compositions comprise amidated metathesized natural oils formed from a metathesized natural oil and at least one amine. The methods comprise providing an amine and providing a metathesized natural oil. The methods further comprise mixing the amine and the metathesized natural oil in the presence of a basic catalyst or heat, causing a reaction between the amine and metathesized natural oil, therein forming the amidated metathesized natural oil.
    Type: Grant
    Filed: February 1, 2016
    Date of Patent: January 16, 2018
    Assignee: Elevance Renewable Sciences, Inc.
    Inventors: Monika Mujkic, Deidra Cade, Choon Woo Lee, Michael S. Starch, Brian J. Swanton
  • Therapeutic compositions
    Patent number: 9861603
    Abstract: Ingenol angelate is a potent anticancer agent, and can be stabilized by dissolving it in an aprotic solvent in the presence of an acidic buffer.
    Type: Grant
    Filed: May 24, 2016
    Date of Patent: January 9, 2018
    Assignee: LEO Laboratories Limited
    Inventors: Marc Barry Brown, Michael Edward Donald Crothers, Tahir Nazir
  • Polyfluorinated compounds acting as bruton tyrosine kinase inhibitors
    Patent number: 9861636
    Abstract: Described herein is a novel series of multi-fluoro-substituted pyrazolopyrimidine compounds or salts thereof. These compounds are Bruton's tyrosine kinase (BTK) inhibitors. These compounds may possess better BTK inhibition selectivity and pharmacokinetic properties. Disclosed herein are the synthesis methods of these compounds. Disclosed herein are novel synthesis methods of the multi-fluoro-substituted benzophenone and substituted phenoxy benzene. Also disclosed are pharmaceutical compositions comprising the BTK inhibitors described herein. The present invention also relates to pharmaceutical formulations comprising the compounds described herein as active ingredients. The present invention also includes the therapeutic methods by administering the BTK inhibitors and their formulations to treat and inhibit autoimmune disease, hypersensitivity disease, inflammatory diseases and cancer.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: January 9, 2018
    Assignee: ZHEJIANG DTRM BIOPHARMA CO. LTD.
    Inventor: Wei He